4th Quarter - Amendment
BLUEBIRD BIO, INC. for BLUEBIRD BIO, INC.
Firm
Client
Income
—
Expenses
$140,000
Expense method
A: Lobbying Disclosure Act definitions
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 4th Quarter - Report | Jan 16, 2024 | $140,000 | Replaced |
| 4th Quarter - Amendment | Apr 3, 2024 | $140,000 | Replaced |
| 4th Quarter - Amendment (this page) | Apr 4, 2024 | $140,000 | Yes |
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
HR 2666 - MVP Act Medicaid Program: Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program (CMS-2434-P) CMMI sought bluebird input on potential gene therapy demo for sickle cell disease beneficiaries of Medicaid
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTINA HARTMAN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.